Allergologia et immunopathologia最新文献

{"title":"Determining specific IgE cutoff values to predict reactions in oral food challenges for cow's milk allergy using the Immulite System.","authors":"Gökhan Yörüsün, Ragıp Dere, Hatice Irmak Celik, Ahmet Selmanoglu, Ozge Yılmaz Topal, Zeynep Sengül Emeksiz, Emine Dibek Mısırlıoglu","doi":"10.15586/aei.v53i6.1422","DOIUrl":"https://doi.org/10.15586/aei.v53i6.1422","url":null,"abstract":"<p><p>The diagnosis of IgE-mediated cow's milk allergy (CMA) involves serum-specific IgE (spIgE), skin prick tests (SPT), and the gold standard oral food challenge (OFC). SpIgE levels are measured using methods such as ImmunoCAP and IMMULITE, with most cutoff data derived from ImmunoCAP. This study aims to determine IMMULITE-specific cutoff values to predict OFC positivity. Patients diagnosed with CMA via OFC between 2019 and 2023 were retrospectively analyzed. Data on demographics, eosinophil counts, total and specific IgE levels, and SPT results were collected. OFC was conducted using yogurt, milk-based formula, or milk-containing muffins. SPTs were performed with commercial extracts (Lofarma®) and pasteurized milk using the prick-to-prick method. SpIgE levels were measured with the Siemens® IMMULITE 2000 Immunoassay System, with values ≥0.35 kU/L considered positive. The study included 50 OFC-positive patients (60% males) and 50 age- and clinically matched controls without objective OFC reactions. The median age at diagnosis was 6 months (IQR: 3-21), and 52% presented with atopic dermatitis. OFC reactions occurred with yogurt in 42 patients (84%), muffins in 6, and milk in 2; 26% of reactions were anaphylaxis. IMMULITE-derived cutoff values were 3.13 kU/L (AUC: 0.776, 72% sensitivity, 72% specificity) for cow's milk spIgE and 1.85 kU/L for casein. SPT enduration cutoffs were 4.25 mm for pasteurized milk and 3.5 mm for commercial extracts. This study provides critical IMMULITE-specific spIgE cutoffs to predict OFC outcomes, offering valuable reference ranges for clinical CMA diagnosis.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"7-13"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of the common pathogenesis of Alzheimer's and nonalcoholic fatty liver disease and exploration of their relationship with immune cells.","authors":"Khizra Jabeen, Muhammad Naveed, Tariq Aziz, Muhammad Saad, Ammena Y Binsaleh, Nawal Al-Hoshani, Maher S Alwethaynani, Mariam Abdulaziz Alkhateeb, Areej A Alhhazmi, Omniah A Mansouri","doi":"10.15586/aei.v53i6.1475","DOIUrl":"10.15586/aei.v53i6.1475","url":null,"abstract":"<p><p>Alzheimer's disease (AD) and nonalcoholic fatty liver disease (NAFLD) are both prominent public health concerns owing to their increasing prevalence and burden on healthcare systems. The interconnected genetic and immunological mechanisms that may cause both of these diseases are poorly understood. This study used broad gene expression datasets to identify similar molecular markers and immunological profiles in AD and NAFLD and evaluate their potential. Using the Gene Expression Omnibus (GEO) database, mRNA expression profiles from patients with AD and NAFLD were analyzed alongside control samples to identify differentially expressed genes (DEGs). Systems biology approaches, including LASSO regression and multivariate logistic regression models, were used to further refine the significance of DEGs. The diagnostic potential of the key genes was evaluated using receiver operating characteristic (ROC) curves, and the immune cell environment was quantified using the Immune Cell Abundance Identifier (ImmuCellAI). We identified 11,278 DEGs, with 3551 upregulated and 7857 downregulated genes. S100A8, CXCL9, and ST8SIA3 have emerged as significant biomarkers of both AD and NAFLD. ROC analysis substantiated the diagnostic value of these markers. Additionally, distinct patterns of immune cell populations have been observed in AD and NAFLD, highlighting potential targets for immunomodulatory therapy. This study elucidates shared molecular and immune mechanisms in AD and NAFLD, offering insights into the pathophysiological underpinnings that could inform the development of novel diagnostic and therapeutic strategies. S100A8, CXCL9, and ST8SIA3 are potential candidates for future clinical application. Further investigation into these genetic discoveries and their immune system effects may lead to a unified strategy for treating these complicated disorders.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"20-31"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate reactions to proton pump inhibitors: Clinical findings and testing outcomes.","authors":"Nurullah Yekta Akçam, Güzin Özden, Leyla Çevirme, Merve Erkoç","doi":"10.15586/aei.v53i6.1463","DOIUrl":"10.15586/aei.v53i6.1463","url":null,"abstract":"<p><strong>Background: </strong>Proton pump inhibitors (PPIs) are identified to cause immediate hypersensitivity reactions and cross-reactivity among them. In this study, we aimed to describe the clinical features of immediate-type hypersensitivity reactions caused by PPIs, the results of drug tests performed with PPIs, and the cross-reactivity between PPIs. There are immediate hypersensitivity reactions with PPIs and there may be cross-reactivity between PPIs. In this study, we aimed to describe the clinical features of immediate-type hypersensitivity reactions caused by PPIs, the results of drug tests performed with PPIs and the cross-reactivity between PPIs.</p><p><strong>Methods: </strong>Adult patients who described an immediate hypersensitivity reaction to PPIs between March 1, 2017 and March 1, 2023 were evaluated.</p><p><strong>Results: </strong>Of the 47 patients included in the study, 89.4% were females, and the suspected PPI in 68% of the patients was lansoprazole. Anaphylaxis accounted for 72.3% of reactions, and the most common reaction was grade 2 (42.6%) according to Ring Messmer. Those who had two or more reactions to the same or different PPI were 51.1% of patients. A positivity rate of 43.8% was observed in the skin prick test with the suspected drug, 33.3% in the intradermal test, and 100% in the provocation test. There is varying potential for cross-reactivity among five different PPIs.</p><p><strong>Conclusions: </strong>İmmediate hypersensitivity reactions are observed among PPIs, particularly to lansoprazole, with the majority of reactions being anaphylaxis. Multiple life-threatening reactions can be prevented by increasing awareness of allergies to PPIs. Cross-reactivities among PPIs are variable, and further studies are needed to elucidate cross-reactivity with PPIs.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"38-45"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral mite anaphylaxis after pizza consumption in a child: A case report and review of the literature.","authors":"Vasiliki Maria Kymioni, Irine Karatsoli, Nikolaos Koronas, Ifigenia Karagiorga, Konstantinos Kakleas","doi":"10.15586/aei.v53i6.1460","DOIUrl":"10.15586/aei.v53i6.1460","url":null,"abstract":"<p><strong>Introduction: </strong>House dust and storage mites are allergens associated with allergic rhinitis and asthma. Oral mite anaphylaxis manifests after ingesting contaminated flour with mites. We present the case of a 13-year-old child who developed anaphylaxis after consuming pizza.</p><p><strong>Case presentation: </strong>A 13-year-old boy presented with respiratory distress after consuming pepperoni pizza, which he had previously tolerated. Skin prick and specific IgE test results revealed sensitization to house dust and storage mites. He passed an oral food challenge (OFC) for pepperoni pizza.</p><p><strong>Discussion: </strong>Anaphylaxis to foods contaminated by mites (also known as \"pancake syndrome\") is often overlooked. In this case, the diagnosis was supported by the skin prick tests and specific IgE, although the flour used for pizza preparation could not be tested. The patient passed an OFC using ingredients from a different source.</p><p><strong>Conclusion: </strong>Oral mite anaphylaxis is an unusual presentation that must be considered when other possible food allergy triggers have been excluded and the patient is sensitized to mites.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"149-152"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-induced fixed urticaria because of hypersensitivity to non steroidal anti-inflammatory drugs.","authors":"Julia Jaque Gómez-Aguado, Alberto Marín Muñoz, Beatriz Castillo Gómez, Luis Moral Gil","doi":"10.15586/aei.v53i6.1457","DOIUrl":"10.15586/aei.v53i6.1457","url":null,"abstract":"<p><p>Drug-induced fixed urticaria (DIFU) is a rare skin reaction, characteri zed by pruritic hives that reappear in the same location after exposure to the triggering drug. In the few cases reported in the literature, it is considered as an atypical variant of fixed drug eruption (FDE). We present the case of a 10-year-old girl with allergic rhinoconjunctivitis, who had experienced three episodes of localized urticaria on the dorsal surface of both arms, 1 hour after taking ibuprofen. These manifestations did not appear when taking paracetamol, which she tolerated. Her father suffers from generalized urticaria to NSAIDs. An oral provocation test (OPT) was performed with ibuprofen, acetylsalicylic acid, and metamizole, which also caused the same fixed-location wheals and subsequent spontaneous resolution. She, however, tolerated an OPT with meloxicam. This case is notable because of the rarity of the DIFU and the familial aggregation of hypersensitivity to NSAIDs. In this case, as in those of DIFU described in the literature, the hives appeared shortly after the drug was administered and resolved rapidly. This feature distinguishes it from FDE, and it resembles acute drug urticaria, as in the patient's father, which raises questions concerning the pathophysiology of DIFU.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"157-161"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elucidating the probiotic strategy with <i>Pediococcus acidilactici</i> BCB1H and <i>Lactiplantibacillus plantarum</i> HMX2 for restoring normal functions of gut and suppressing inflammation in a DSS-induced colitis animal model.","authors":"Jasra Naseeb, Muti Ur Rehman, Zhennai Yang, Tariq Aziz, Manal F Elkhadragy, Wafa A Alshehri, Areej A Alhhazmi, Maher S Alwethaynani, Hajar Al Qadeeb, Shaza N Alkhatib, Khaloud Mohammed Alarjani, Abeer M Alghamdi","doi":"10.15586/aei.v53i6.1509","DOIUrl":"10.15586/aei.v53i6.1509","url":null,"abstract":"<p><strong>Background: </strong>Several inflammatory diseases, including colitis, are treated via probiotics but still the mechanism is not clear.</p><p><strong>Objective: </strong>This study aimed to restore normal functioning of the gut and ameliorate inflammation in dextran sulfate sodium (DSS)-induced colitis mice via the probiotic intervention of <i>Pediococcus acidilactici</i> (<i>P. acidilactici</i>) BCB1H and <i>Lactiplantibacillus plantarum</i> (<i>L. plantarum</i>) HMX2.</p><p><strong>Material and methods: </strong><i>L. plantarum</i> HMX2 and <i>P. acidilactici</i> BCB1H showed a remarkable reduction in the symptoms of DSS-induced colitis, including weight loss, shortening and damage of the colon, decreased tight junction protein, and pro-inflammatory cytokines in the blood of mice. Two treatment groups were administered with probiotic strains based on animal weight for a duration of 28 days; however, prior to this, DSS was induced.</p><p><strong>Results: </strong>After consuming both probiotics, the levels of inflammatory markers, such as tumour necrosis factor alpha (TNF-α) and interleukins (IL-1β) exhibited a noticeable decline, indicating a reduction in inflammation. The Disease Activity indices for both probiotic-treated groups (<i>P. acidilactici</i> BCB1H- and <i>L. plantarum</i> HMX2-treated groups) were significantly lower (1±0.45, 1±0.36, 3±0.08, 1±0.18, respectively) than that for the DSS-treated group. Both these treatment strains significantly affected the markers of oxidative stress and inflammation (i.e., malondialdehyde [MDA], superoxide dismutase [SOD], and myeloperoxidase [MPO], compared to the intoxicated group. Similarly, the BCB1H- and HMX2-treated groups showed partial recovery, with improved hepatocyte structure and reduced inflammatory cell infiltration, compared to the intoxicated group. Polymerase chain reaction results of gel analysis showed crucial indicators that measure both colonic integrity and inflammation across four experimental groups of colitis-induced mice. Pro-inflammatory cytokines (TNF-α and IL-1β), E-cadherin, and MUC2 mucin served as evaluated markers across experimental groups.</p><p><strong>Conclusion: </strong>Increased expression of these genes suggests that both probiotic strains successfully enhanced and restored normal functions of the gut and suppressed inflammation. This could be attributed to the combined immunomodulatory action of probiotics.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"191-205"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring genetic linkage between rheumatoid arthritis and systemic lupus erythematosus through biological networks and prioritizing omega-3 fatty acids as a potent therapeutic.","authors":"Muhammad Naveed, Syed Murtaza Ali, Tariq Aziz, Syeda Izma Makhdoom, Sana Rehman Cheema, Mariam Abdulaziz Alkhateeb, Maher S Alwethaynani, Seham O Alsulami, Hanan Abdulrahman Sagini, Omniah A Mansouri","doi":"10.15586/aei.v53i6.1492","DOIUrl":"10.15586/aei.v53i6.1492","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic autoimmune diseases characterized by persistent inflammation and progressive tissue damage, posing significant challenges to effective treatment. To gain deeper insights into their shared molecular mechanisms, we performed an integrative bioinformatics investigation aimed at uncovering common pathways and therapeutic targets. Using a cutoff of p-value < 0.05 and Log2 FC > 1, differential gene expression analysis identified 1178 DEGs in RA and 7783 DEGs in SLE, with 358 genes common to both diseases. Construction of a protein-protein interaction network revealed several hub genes, including <i>PDE4A, H1-10, H4C6</i>, and <i>PIP</i>, which were highly interconnected and clustered into functional modules. Molecular docking analysis demonstrated that alpha linolenic acid (ALA) exhibited strong binding affinity toward these key proteins, with binding energies ranging from -8.3 to -9.4 kcal/mol. Toxicity profiling further suggested that ALA possesses a favorable safety profile, showing minimal risks of hepatotoxicity, neurotoxicity, and related adverse outcomes. Functional enrichment pointed to the involvement of common signaling cascades, particularly the cAMP and TGF-β pathways, as potential therapeutic avenues. Collectively, our findings highlight ALA as a promising therapeutic candidate capable of modulating shared molecular drivers in RA and SLE. Further in vitro and in vivo validation is essential to confirm its mechanistic effects and therapeutic potential for clinical translation.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"61-72"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare outcome following a bee sting: Total alopecia.","authors":"Ceren Kaplankıran, Begüm Görgülü Akın, Şadan Soyyiğit","doi":"10.15586/aei.v53i6.1490","DOIUrl":"10.15586/aei.v53i6.1490","url":null,"abstract":"<p><p>Following bee stings, multiple case reports have described the onset of autoimmune-related conditions, including myasthenia gravis, nephrotic syndrome, Henoch-Schönlein purpura, myocardial infarction, cerebrovascular events, and localized alopecia, typically within a few days, indicating that bee venom may play a role in triggering autoimmunity. We report a rare case of total alopecia occurring within ten days after a bee sting. While the literature includes one prior case of total alopecia following bee sting-induced anaphylaxis, our case is distinct in that the patient developed total alopecia in the absence of any hypersensitivity reactions, suggesting a potential immunomodulatory or exacerbating effect of the bee sting on the immune system.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"153-156"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alteration of triggers and symptoms by age group in childhood and adolescence anaphylaxis.","authors":"Meltem Comert, Tugba Guler, Hasibe Artac, Ilknur Kulhas Celik","doi":"10.15586/aei.v53i6.1417","DOIUrl":"10.15586/aei.v53i6.1417","url":null,"abstract":"<p><strong>Background: </strong>Anaphylaxis is a severe, potentially fatal, systemic hypersensitivity reaction induced by various triggers.</p><p><strong>Objective: </strong>Only a few studies have examined the clinical manifestations of childhood anaphylaxis across different age groups. We aimed to evaluate, according to age group and trigger, the clinical features of anaphylaxis in pediatric patients.</p><p><strong>Methods: </strong>We retrospectively evaluated 130 children diagnosed with anaphylaxis over 11 years.</p><p><strong>Results: </strong>The median age of the patients was 10 years (min-max: 0.5-17.8), and 83 (63.8%) were male. Regarding age groups, 23 (17.7%) of the patients were infants, 26 (20%) were preschoolers, 31 (23.8%) were school-age children, and 50 (38.5%) were adolescents. Among the causes with known triggers, the most prevalent trigger was identified as food- affecting 44 (33.8%) cases-followed by drugs (34 cases, 26.2%) and venoms (18 cases, 13.8%). There was a statistically significant relationship between age groups and triggers (p < 0.001). The triggering role of drugs and venoms was found to be low in infants. Also, the infant group had significantly lower risks of venom-induced and drug-induced anaphylaxis compared to the adolescent group. The top three triggers identified in our patients were compared according to the system involved, and a statistically significant relationship was found between triggers and cardiovascular findings (p = 0.006).</p><p><strong>Conclusion: </strong>The etiology of anaphylaxis may vary by age group. Depending on the trigger, it may also have different clinical manifestations.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"86-93"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First successful desensitization with Abemaciclib in an adult patient with breast cancer: A case report.","authors":"Merve Hörmet İğde, Şule Çelik Kamacı, Pelin Korkmaz, İlkim Deniz Toprak, Özdemir Can Tüzer, Osman Ozan Yeğit, Derya Ünal, Semra Demir, Aslı Gelincik","doi":"10.15586/aei.v53i6.1396","DOIUrl":"10.15586/aei.v53i6.1396","url":null,"abstract":"<p><p>Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is an effective targeted therapy for hormone receptor-positive (HR+), HER2-negative, advanced or metastatic breast cancer. While nonimmediate hypersensitivity reactions (NIHRs) have been reported, no immediate hypersensitivity reactions (IHRs) to abemaciclib have been documented to date. Here, we report the first successful desensitization protocol for a patient who developed IHR to abemaciclib. A 75-year-old female with stage II breast cancer underwent a partial mastectomy followed by chemotherapy. Abemaciclib was initiated as part of adjuvant treatment. One hour after the third dose, she presented to the emergency department with lip swelling and urticaria. Symptoms resolved following the administration of intravenous methylprednisolone (0.5 mg/kg) and maleate pheniramine (45.5 mg/mL). Skin prick testing with abemaciclib was negative; however, a drug provocation test led to recurrence of urticaria at a cumulative dose of 150 mg. Given the clinical necessity of abemaciclib and the lack of alternatives, a 12-step desensitization protocol was implemented using 300 mg of abemaciclib dissolved in 100 mL of distilled water. The protocol was completed over 4 h, with no complications observed during the procedure or in the subsequent 3-month follow-up. The patient continued abemaciclib at 300 mg/day without recurrence of symptoms. This case highlights the importance of drug desensitization in oncology, particularly in patients for whom no alternative therapies are available.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 6","pages":"146-148"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145501561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}